Novo Nordisk’s cannabinoid CB1 receptor blocker ... that the molecule suffers from some of the same problems that held back CB1 blockers in the past. European authorities withdrew the approval ...

The company is also grappling with competition from Eli Lilly. (Image Credits: PIxabay) Novo Nordisk on Wednesday announced that it plan to file its experimental next-generation obesity drug ...

COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the ...

A drug that Novo Nordisk acquired to expand its prospects in metabolic disorders has failed a mid-stage clinical trial in diabetic kidney disease. The results also showed signs of a ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE:NVO) for violations of 10(b ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks. Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate ...

Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the performance in 2024, where 26% sales growth reflects that more than 45 million people are now benefiting from our treatments.

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

Per-share earnings adjusted for one-time items totaled $5.32, easily topping the $5.01 that Wall Street was looking ... Wegovy from the Danish drugmaker Novo Nordisk, which also reported strong ...